TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33570228

Group type: EXPERIMENTAL
Intervention: Phyllanthus emblica capsule (500 mg) twice daily for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo twice daily for 12 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Phyllanthus emblica capsule (500 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 35972854

Group type: EXPERIMENTAL
Intervention: Positive Health Check (N = 397)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Standard of care (N = 402)
Number of subjects: 799
Study: 33962564

Group type: EXPERIMENTAL
Intervention: Case-finding using MDI
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual clinical assessment
Number of subjects: 500
Study: 32383070

Group type: EXPERIMENTAL
Intervention: Decreased birthweight (1 SD lower)
Number of subjects: 183433

Group type: COMPARATOR
Intervention: Genetically instrumented birthweight (1 SD lower)
Number of subjects: 183433

Group type: COMPARATOR
Intervention: Genetically determined low birthweight (1 SD lower)
Number of subjects: 183433
Study: 33494637

Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT) only
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) including intra-arterial thrombolysis and mechanical thrombectomy (MT; ±IVT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Mechanical thrombectomy (MT) only
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after 2015
Number of subjects: 169
Study: 34411636

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard multimodal analgesia
Number of subjects: 80
Study: 34032043

Group type: EXPERIMENTAL
Intervention: 1 ml compound betamethasone injection
Number of subjects: 116

Group type: COMPARATOR
Intervention: 4 ml hyaluronic acid and 1 ml compound betamethasone injection
Number of subjects: 116
Study: 32437187

Group type: EXPERIMENTAL
Intervention: Meaningful speech
Number of subjects: 2

Group type: COMPARATOR
Intervention: Meaningless (foreign) speech
Number of subjects: 2

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 2
Study: 35256040

Group type: COMPARATOR
Intervention: Maternal report of stress
Number of subjects: 548

Group type: COMPARATOR
Intervention: Maternal psychological appraisals of stress
Number of subjects: 548

Group type: COMPARATOR
Intervention: Maternal reports of environmental stressors
Number of subjects: 548
Study: 34385478

Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cathodal stimulation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 3
Study: 34999335

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid, carotenoid and vitamin E supplementation (1 g fish oil, 430 mg DHA, 90 mg EPA, 22 mg carotenoids, 15 mg vitamin E)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid, carotenoid and vitamin E supplementation
Number of subjects: 30
Study: 34687964

Group type: EXPERIMENTAL
Intervention: Verum tDCS (2 mA for 20 min over DLPFC) combined with alcohol cue ICT
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sham tDCS combined with any ICT
Number of subjects: 125

Group type: COMPARATOR
Intervention: Any tDCS (verum or sham) combined with neutral ICT
Number of subjects: 125
Study: 35073975

Group type: EXPERIMENTAL
Intervention: FACAM intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 33388700

Group type: EXPERIMENTAL
Intervention: Treatment-as-usual plus aerobic walking (TAW)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 67
Study: 35019055

Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment (MBT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 113
Study: 36141922

Group type: EXPERIMENTAL
Intervention: Personalized, dynamic, and stratified intervention strategy based on an app
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group receiving the same intervention components of the app without the dynamic, personalized, and stratified function
Number of subjects: 426
Study: 32280484

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 35723758

Group type: EXPERIMENTAL
Intervention: Pemetrexed + treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Pemetrexed - treatment
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pemetrexed + treatment (among patients with at least four lines of prior treatment)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Pemetrexed - treatment (among patients with at least four lines of prior treatment)
Number of subjects: 144
Study: 34601077

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HRW) 0.5 L per day (15 ppm of hydrogen)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control water (0 ppm of hydrogen)
Number of subjects: 40
Study: 32886901

Group type: EXPERIMENTAL
Intervention: Upfront lanreotide (120 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active surveillance followed by lanreotide after progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lanreotide price reduction scenarios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide long-acting release (LAR)
Number of subjects: 0
Study: 35430631

Group type: EXPERIMENTAL
Intervention: Total menthol ban
Number of subjects: 47

Group type: COMPARATOR
Intervention: Menthol cigarette ban
Number of subjects: 47

Group type: COMPARATOR
Intervention: Menthol ban conditions
Number of subjects: 47
Study: 32947578

Group type: EXPERIMENTAL
Intervention: Healthy Caregivers‐Healthy Children (HC2) phase 1 intervention
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: Healthy Caregivers‐Healthy Children (HC2) phase 2 intervention
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Control group for phase 1
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Control group for phase 2
Number of subjects: 2049
Study: 36224646

Group type: EXPERIMENTAL
Intervention: 2-channel PCA (16 μg/kg of fentanyl, 2 mg/kg of ketorolac, 12 mg of ondansetron)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 1-channel PCA (16 μg/kg of fentanyl, normal saline in continuous channel)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 2-channel PCA
Number of subjects: 84

Group type: COMPARATOR
Intervention: 1-channel PCA
Number of subjects: 84
Study: 35285809

Group type: EXPERIMENTAL
Intervention: mHealth ketogenic diet app intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: mHealth app engagement
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: breath acetone levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: compliance with weight measurements and app engagement
Number of subjects: 75
Study: 34590929

Group type: EXPERIMENTAL
Intervention: Myo 2 g twice daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Met 850 mg twice daily
Number of subjects: 102
Study: 33686715

Group type: EXPERIMENTAL
Intervention: Individual self-explanations
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dyadic explanations
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition (listened to the lecture once)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition (listened to the lecture twice)
Number of subjects: 120
Study: 32732573

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Autologous blood
Number of subjects: 119

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 119
Study: 36037999

Group type: EXPERIMENTAL
Intervention: Digoxin administration in patients with heart failure (39 patients, 10.5%)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Digoxin administration in patients without heart failure (11 patients, 3.5%)
Number of subjects: 698
Study: 33188745

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33985509

Group type: EXPERIMENTAL
Intervention: Hybrid Comprehensive Telerehabilitation (HCTR)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 782
Study: 32614723

Group type: EXPERIMENTAL
Intervention: Regular physiotherapy (PT) and gaming
Number of subjects: 32

Group type: COMPARATOR
Intervention: Regular physiotherapy (PT)
Number of subjects: 32
Study: 35771851

Group type: EXPERIMENTAL
Intervention: Music therapy (singing lessons)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Physical activity (active control)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No intervention (passive control)
Number of subjects: 135
Study: 32912861

Group type: EXPERIMENTAL
Intervention: Current (past 7 day) use of HTP at baseline
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Persistent HTP users from baseline to 1‐month/3‐month follow‐up
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Use of smoking cessation service between baseline and 3‐month follow‐up
Number of subjects: 1213
Study: 34957385

Group type: EXPERIMENTAL
Intervention: FTC/TDF+COLCH+ROSU
Number of subjects: 649

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: COLCH+ROSU
Number of subjects: 649
Study: 35972301

Group type: EXPERIMENTAL
Intervention: CMO pharmaceutical intervention model
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular treatment (Control Group)
Number of subjects: 100
Study: 32021152

Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 0
Study: 33517434

Group type: EXPERIMENTAL
Intervention: High-fidelity human patient simulator
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no simulation method)
Number of subjects: 61
Study: 32108263

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2640 IU/d)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 34709147

Group type: EXPERIMENTAL
Intervention: Automated metrics‐based summative feedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard instructions
Number of subjects: 24
Study: 33460358

Group type: EXPERIMENTAL
Intervention: 3‐min light‐intensity walking every 30 min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 6‐min light‐intensity walking every 60 min
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prolonged sitting (SIT)
Number of subjects: 21
Study: 35470371

Group type: EXPERIMENTAL
Intervention: Varenicline plus naltrexone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Varenicline plus placebo
Number of subjects: 26
Study: 33851765

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) using Gallium‐aluminum‐arsenide (GaAlAs) diode laser, applied immediately after surgery and for 15 days.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no PBMT treatment).
Number of subjects: 93
Study: 35915472

Group type: EXPERIMENTAL
Intervention: Immediate induction of labor
Number of subjects: 185

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Immediate induction of labor or Expectant management
Number of subjects: 185
Study: 33518080

Group type: COMPARATOR
Intervention: 0 mg ALA/bird per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 15 mg ALA/bird per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 40 mg ALA/bird per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 70 mg ALA/bird per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 95 mg ALA/bird per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 120 mg ALA/bird per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 145 mg ALA/bird per day
Number of subjects: 42
Study: 35745214

Group type: EXPERIMENTAL
Intervention: Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 supplementation (1 × 10^10 CFU)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo group (same product without probiotics)
Number of subjects: 72
Study: 33789145

Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32388067

Group type: EXPERIMENTAL
Intervention: Locking Plate (LP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple Lag Screw (MLS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DHS + MLS (mixed fixture)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HemiArthroplasty (HA)
Number of subjects: 20
Study: 34120232

Group type: EXPERIMENTAL
Intervention: FERAK brace
Number of subjects: 38

Group type: COMPARATOR
Intervention: Denis Browne boot (DBB) brace
Number of subjects: 38
Study: 32621538

Group type: EXPERIMENTAL
Intervention: Peripheral vestibular disorders overall
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Meniere's disease
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Benign paroxysmal positional vertigo
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Vestibular neuritis
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Other or unspecified peripheral vestibular dizziness
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Gender ratios for Meniere's disease
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Gender ratios for vestibular neuritis
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Gender ratios for other peripheral vestibular dizziness
Number of subjects: 59986

Group type: EXPERIMENTAL
Intervention: Urbanization levels
Number of subjects: 59986
Study: 35298696

Group type: EXPERIMENTAL
Intervention: Foam rolling
Number of subjects: 38

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 38
Study: 34388977

Group type: EXPERIMENTAL
Intervention: Combination of urine and breath samples
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Urine samples only
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Breath samples only
Number of subjects: 246
Study: 36454263

Group type: EXPERIMENTAL
Intervention: GalNAc3-conjugated 2'-O-methoxyethyl-modified ASOs
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 33595409

Group type: EXPERIMENTAL
Intervention: 250 ppm QY
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 500 ppm QY
Number of subjects: 480

Group type: COMPARATOR
Intervention: 0 ppm QY (Control)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: All QY treatments (250 and 500 ppm)
Number of subjects: 480
Study: 32163557

Group type: EXPERIMENTAL
Intervention: Chlorambucil-obinutuzumab (ClbG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab (VenG)
Number of subjects: 0
Study: 34785484

Group type: EXPERIMENTAL
Intervention: Phone-sized screen
Number of subjects: 52

Group type: COMPARATOR
Intervention: Laptop-sized screen
Number of subjects: 52
Study: 34388515

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 119

Group type: COMPARATOR
Intervention: Lomustine
Number of subjects: 119
Study: 33231663

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (n = 410)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo (5.5% saline) (n = 408)
Number of subjects: 818
Study: 34360464

Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT) under normobaric normoxia (SL: PIO2 150 mmHg, FIO2 0.209)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT) under moderate hypoxia (MH: PIO2 117 mmHg, FIO2 0.154)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT) under severe hypoxia (SH: PIO2 87 mmHg, FIO2 0.112)
Number of subjects: 19
Study: 32595060

Group type: EXPERIMENTAL
Intervention: GLASS Ⅰ, Ⅱ, and Ⅲ groups (Endovascular treatment)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: GLASS Ⅲ (Endovascular treatment)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: GLASS scoring system (Endovascular treatment)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: GLASS score groups (Endovascular treatment)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Development group (Endovascular treatment)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Validation sample (Endovascular treatment)
Number of subjects: 257
Study: 36274468

Group type: EXPERIMENTAL
Intervention: Abdominal massage for 3 days, twice a day, for 15 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 60
Study: 34629461

Group type: EXPERIMENTAL
Intervention: Distal femoral triangle and distal adductor canal blocks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 77
Study: 33002305

Group type: EXPERIMENTAL
Intervention: Lung metastasectomy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no lung metastasectomy)
Number of subjects: 93
Study: 32742507

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (twice daily with a maximum of 180 mmHg for 5 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cuff inflation to 30 mmHg (sham preconditioning)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Number of subjects: 200
Study: 34009847

Group type: EXPERIMENTAL
Intervention: tDCS with various electrode montages
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 34636151

Group type: EXPERIMENTAL
Intervention: Initial-onset LN (<12 months after development of SLE, n=49)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Delayed-onset LN (≥12 months after development of SLE, n=17)
Number of subjects: 66
Study: 32700292

Group type: EXPERIMENTAL
Intervention: Gross motor skills assessment (Korper Koordinationstest für Kinder and Bruininks‐Oseretsky Test of Motor Proficiency ‐ 2nd Edition)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness assessment (20‐meter Shuttle Run Test)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: VSWM-related brain activation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Behavioral results
Number of subjects: 80
Study: 36041773

Group type: EXPERIMENTAL
Intervention: ICS withdrawal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (ICS continuation)
Number of subjects: 40
Study: 32437332

Group type: EXPERIMENTAL
Intervention: ID + IL-12 (1.6 mg ID + 0.4 mg pIL-12)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: IM + IL-12 (8 mg IM + 1 mg pIL-12)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ID no IL-12 (1.6 mg ID)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ID + IL-12
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: IM + IL-12
Number of subjects: 89
Study: 35975728

Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multimodal telemedicine approach (as mentioned in a referenced trial)
Number of subjects: 0
Study: 33439265

Group type: EXPERIMENTAL
Intervention: Bimagrumab (10 mg/kg up to 1200 mg in 5% dextrose solution) every 4 weeks for 48 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (5% dextrose solution) every 4 weeks for 48 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bimagrumab
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 35253125

Group type: COMPARATOR
Intervention: Discharge on postoperative day (POD) 2
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Discharge on postoperative day (POD) 3
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Discharge on postoperative day (POD) ≥4
Number of subjects: 1391
Study: 33387632

Group type: EXPERIMENTAL
Intervention: Low-level tragus stimulation (LLTS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study: 32315969

Group type: EXPERIMENTAL
Intervention: Comic book-based educational program (autonomous reading and character interpretation methodology)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Character interpretation methodology
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Three months follow-up
Number of subjects: 83
Study: 34333237

Group type: EXPERIMENTAL
Intervention: Postoperative detectable ctDNA
Number of subjects: 23

Group type: COMPARATOR
Intervention: Postoperative undetectable ctDNA
Number of subjects: 23
Study: 32359940

Group type: EXPERIMENTAL
Intervention: Physical fatigue condition
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 19
Study: 36206262

Group type: EXPERIMENTAL
Intervention: Prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours
Number of subjects: 284

Group type: COMPARATOR
Intervention: Usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C)
Number of subjects: 284
Study: 33909484

Group type: EXPERIMENTAL
Intervention: Mirror illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No mirror illusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 35484523

Group type: EXPERIMENTAL
Intervention: Fitbit + behavioral counselling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fitbit-only control group
Number of subjects: 120
Study: 34554693

Group type: EXPERIMENTAL
Intervention: Single-shot thoracic paravertebral block combined with intravenous analgesia (Group P)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Continuous thoracic epidural analgesia (Group E)
Number of subjects: 96
Study: 35894828

Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 320

Group type: COMPARATOR
Intervention: DHCA/retrograde cerebral perfusion (RCP)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion strategy
Number of subjects: 320
Study: 32815436

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0